Max Robotics — Global Service Robot Directory + US Certification

About

Clinton A. Medbery is a radiation oncologist whose research has made meaningful contributions to the field of prostate cancer radiotherapy, with a particular focus on stereotactic body radiotherapy (SBRT) as a precise and effective treatment modality. His work has been instrumental in establishing the long-term efficacy and safety profile of prostate SBRT, especially in community-based clinical settings — a distinction that broadens the real-world applicability of his findings. Medbery has played a prominent role in a landmark multi-institutional prospective trial enrolling 259 low- and intermediate-risk prostate cancer patients across up to 18 institutions, with 90% treated in community facilities. His contributions span 5-year, and now 10-year, outcome analyses from this trial, providing some of the most mature longitudinal data available for high-dose "HDR-like" prostate SBRT. His 2018 secondary analysis investigating patient and dosimetric predictors of genitourinary and bowel quality of life — his most cited work with 25 citations — offers clinically actionable insights for minimizing treatment-related side effects. Collectively, his research supports SBRT as a durable, scalable treatment option and helps guide personalized care for prostate cancer patients nationwide.